DAX ®11.654,51+0,87%TecDAX ®2.669,04+0,71%S&P FUTURE2.775,00+0,27%Nasdaq 100 Future7.149,75+0,61%
finanztreff.de

DGAP-Adhoc: MagForce AG receives FDA Investigational Device Exemption approval to conduct a clinical trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 2 min. | Text vorlesen Stop Pause Fortsetzen
DGAP-Ad-hoc: MagForce AG / Key word(s): Study
MagForce AG receives FDA Investigational Device Exemption approval to
conduct a clinical trial with NanoTherm Therapy as Focal Ablation Treatment
for Intermediate Risk Prostate Cancer

10-Feb-2018 / 10:38 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*MagForce receives FDA Investigational Device Exemption approval to conduct
a clinical trial with* *NanoTherm Therapy as Focal Ablation Treatment for
Intermediate Risk Prostate Cancer *

*Berlin, Germany and Nevada, USA, February 10, 2018* - MagForce AG
(Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, together with its
subsidiary MagForce USA, Inc., announces that it has received U.S. Food and
Drug Administration (FDA) Investigational Device Exemption (IDE) approval to
conduct a clinical trial with NanoTherm therapy as focal ablation treatment
for intermediate risk prostate cancer.

The approval of this IDE now allows MagForce to conduct a pivotal clinical
evaluation with the Company's innovative NanoTherm therapy at selected
medical centers in the US. MagForce anticipates to initiate patient
enrollment in this study in the coming months.

The purpose of this focal thermal ablation registration study that will
enroll up to 120 men in a single arm study is to demonstrate that NanoTherm
can focally ablate cancer lesions for patients who have advanced to
intermediate risk prostate cancer stage and are under active surveillance.
By focally ablating these cancer lesions, it is anticipated that patients
will be able to be maintained in Active Surveillance Programs and to avoid
definitive therapies such as surgery or whole gland radiation with their
well-known side effects.

Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com

10-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MagForce AG
Max-Planck-Straße 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt
(Scale), Stuttgart, Tradegate Exchange

End of Announcement DGAP News Service

653291 10-Feb-2018 CET/CEST



(END) Dow Jones Newswires

February 10, 2018 04:43 ET ( 09:43 GMT)
Werbung

Das könnte Sie auch interessieren

Werbung
Werbung

News-Suche

Suchbegriff:
Werbung

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Börse Stuttgartschliessen
Börse Stuttgart

Gewinnen Sie pures Gold!

Unter allen Teilnehmern an der Anlegerumfrage verlost der Börse Stuttgart Anlegerclub Gold im Gesamtwert von über 1000 Euro.

Jetzt kostenlos anmelden und mitmachen!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 43 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen
schliessen